Toxins and radionuclides coupled to IGF-1 receptor ligands for treatment of cancer
US8920777B2 · kind B2 · utility
0Cited by
4References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 15, 2011 |
| Grant date | Dec 30, 2014 |
| Priority date | — |
| Expiry date | Aug 15, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides an insulin-like growth factor-1 (IGF-1) receptor ligand carrying a therapeutic radionuclide for treatment of cancer is provided. A method of treating cancer using the IGF-1 receptor ligand carrying a therapeutic radionuclide is also provided. An anti-cancer therapeutic agent containing an IGF-1 receptor ligand linked to a toxin is also provided, as are methods of using the toxin conjugates for treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.